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Abstract
This study analyzed GE Centricity Electronic Medical Record (EMR) data to examine the effects of body mass
index (BMI) and obesity, key risk factor components of metabolic syndrome, on the prevalence of 3 chronic
diseases: type II diabetes mellitus, hyperlipidemia, and hypertension. These chronic diseases occur with high
prevalence and impose high disease burdens. The rationale for using Centricity EMR data is 2-fold. First, EMRs
may be a good source of BMI/obesity data, which are often underreported in surveys and administrative
databases. Second, EMRs provide an ideal means to track variables over time and, thus, allow longitudinal
analyses of relationships between risk factors and disease prevalence and progression. Analysis of Centricity
EMR data showed associations of age, sex, race/ethnicity, and BMI with diagnosed prevalence of the 3 con-
ditions. Results include uniform direct correlations between age and BMI and prevalence of each disease;
uniformly greater disease prevalence for males than females; varying differences by race/ethnicity (ie, African
Americans have the highest prevalence of diagnosed type II diabetes and hypertension, while whites have the
highest prevalence of diagnosed hypertension); and adverse effects of comorbidities. The direct associations
between BMI and disease prevalence are consistent for males and females and across all racial/ethnic groups.
The results reported herein contribute to the growing literature about the adverse effects of obesity on chronic
disease prevalence and about the potential value of EMR data to elucidate trends in disease prevalence and
facilitate longitudinal analyses. (Population Health Management 2010;13:151–161)
Introduction
There is a vast literature on the etiology of type IIdiabetes mellitus, hyperlipidemia, and hypertension. A
key concept in understanding the origin and course of these
chronic conditions is metabolic syndrome, which refers to a
cluster of risk factors for cardiovascular disease (CVD). These
risk factors were originally described by Reaven as a com-
posite of obesity, dyslipidemia, hypertension, and hypergly-
cemia. The exact measures and thresholds for these
components have undergone several iterations in the past 2
decades.1 Currently, the most frequently used definitions are
those developed by (1) the World Health Organization in
1999,2 with important later revisions by the European Group
for the Study of Insulin Resistance in 19993; (2) the National
Cholesterol Education Program Adult Treatment Panel III in
20014; and (3) the International Diabetes Federation (IDF) in
2006.5 It remains arguable whether the composite metabolic
syndrome categorization is better than the sum of its parts at
predicting CVD, as well as whether the latest definitional it-
eration (IDF) lends additional predictive power to older def-
initions.6,7 One obvious advantage of the IDF definition,
however, may be the recent recognition that one measure
of obesity may not fit all ethnicities; hence, the IDF defini-
tion of metabolic syndrome may be a more globally useful
definition.
1Thomas Jefferson University School of Population Health, Philadelphia, Pennsylvania.
Johnson & Johnson, 2Corporate Office of Science and Technology, and 5Office of Evidence Based Medicine, Medical Device and
Diagnostics New Brunswick, New Jersey.
3S2Statistical Solutions, Inc., Cincinnati, Ohio.
4Ethicon Endo-Surgery, Inc., New Brunswick, New Jersey.
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The various definitions and indicators noted have been
used to assess the prevalence of metabolic syndrome and the
clinical outcomes of patients in several large observational
and interventional cohorts.8–13 Among the more prominent
data sets are those of the Framingham Study, including the
Framingham Offspring Study, in the United States, and the
General Practice Research Database in the United Kingdom,
the largest non-US database of ‘‘anonymized’’ primary care
medical records.14,15
Turning to the effects of body mass index (BMI) and
obesity, Bays and colleagues16 explored the relationships
between BMI and prevalence of diabetes, hypertension, and
dyslipidemia, examined BMI distributions among patients
with these conditions, and compared results from 2 national
surveys: (1) the screening questionnaire-based 2004 Study to
Help Improve Early evaluation and management of risk
factors Leading to Diabetes (SHIELD), and (2) the interview,
clinical, and laboratory data of the 1999–2002 National
Health and Nutrition Examination Surveys (NHANES). Bays
et al found that mean BMI was virtually identical in the 2
data sets: 27.8 kg/m2 for SHIELD and 27.9 kg/m2 for
NHANES. Increased BMI was associated with increased
prevalence of diabetes mellitus, hypertension, and dyslipi-
demia in both studies (P< 0.001). For each condition, more
than 75% of patients had a BMI> 25 kg/m2. Estimated
prevalence of diabetes mellitus and hypertension was similar
in both studies, while prevalence of dyslipidemia was sub-
stantially higher in NHANES than SHIELD.
McTigue et al17 studied 90,185 women who participated in
the Women’s Health Initiative to determine how cardiovas-
cular and mortality risks differ across clinical weight cate-
gories in women, especially the extreme obesity category. The
duration of follow-up averaged 7.0 years (1993–2004). The
researchers found that, among women, extreme obesity
prevalence differed with race/ethnicity, from 1% among
Asians and Pacific Islanders to 10% among black women. All-
cause mortality rates per 10,000 person-years were 68.49 (95%
confidence interval [CI], 65.26–71.68) for normal BMI (<25),
71.16 (95% CI 67.68–74.82) for overweight (25BMI< 30),
84.47 (95% CI 78.90–90.42) for obesity 1 (30BMI< 35),
102.85 (95% CI 92.90–113.86) for obesity 2 (35BMI< 40),
and 116.85 (95% CI 103.36–132.11) for extreme obesity
(BMI 40). Analyses adjusting for the effects of age, smoking,
educational achievement, region of the United States, and
physical activity level showed that weight-related all-cause
mortality risk, coronary heart disease (CHD) mortality, and
CHD incidence did not differ by race/ethnicity. Such adjusted
analyses among both white and black participants showed
positive trends in all-cause mortality and CHD incidence with
increasing weight. Much of the obesity-related mortality and
CHD risk was mediated by diabetes, hypertension, and hy-
perlipidemia. For white women, weight-related all-cause
mortality risk varied by age, with obesity producing less risk
among older women. McTigue and colleagues advocate using
more weight categories and conclude that ‘‘considering obe-
sity as a body mass index of 30 or higher may lead to misin-
terpretation of individual and population risks.’’
Sturm18 asserts that ‘‘the most serious health problems are
not associated with overweight or moderate obesity…but
with clinically severe or morbid obesity (eg, more than 100
pounds (45 kg) overweight).’’ He uses data from the Beha-
vioral Risk Factor Surveillance System to estimate trends for
extreme weight categories (BMI> 40 and BMI> 50) for the
period from 1986–2005 in the United States and assesses
whether trends have changed since 2000. Sturm finds that
from 2000–2005, while the prevalence of obesity (self-
reported BMI> 30) increased by 24%, the prevalence of
BMI> 40 increased by 50% and the prevalence of BMI> 50
increased by 75%. Sturm concludes that ‘‘the heaviest BMI
groups have been increasing at the fastest rates for 20 years’’
and that ‘‘because comorbidities and resulting service use are
much higher among severely obese individuals, the widely
published trends for overweight/obesity underestimate the
consequences for population health.’’
The analyses reported herein employ GE Centricitya
electronic medical record (EMR) data to assess the preva-
lence of the 3 chronic conditions and the role of obesity in
their etiology and progression. The GE database comprises
the ‘‘anonymized’’ longitudinal medical records of over 6
million patients, is considered one of the few high-quality
patient databases available commercially, and is generally
representative of the population of the United States.
A growing proportion of ambulatory care physician
practices in the United States are adopting EMR systems to
support various clinical processes including documentation
of patient encounters and secure exchange of data with other
providers. In 2007, the GE Centricity EMR was used by more
than 20,000 clinicians in 49 states for medical record docu-
mentation for approximately 30 million patients. These
electronic records contain a wide range of demographic and
clinical variables. The structured user interface supports
consistent and accurate documentation by physicians and
thus promotes internal data validity for each patient and for
the aggregate. As with other EMRs, a significant attribute of
Centricity is its capacity to track patients’ clinical conditions
over time and, thus, to support longitudinal multivariate
analytic designs, including retrospective cohort studies.
Cumulatively, these attributes of Centricity and other EMRs
make them rich resources for population health and out-
comes research.
Research interest in the GE Centricity database is evident
in the growing peer-reviewed literature employing this
resource. Our review of recently published peer-reviewed
literature employing GE Centricity EMR data revealed 2
especially useful and relevant studies. First, Brixner et al19
used clinical, diagnostic, and treatment/prescription infor-
mation in the Centricity database to examine the prevalence
of cardiometabolic risk (CMR) factors that contribute to
metabolic syndrome in the primary care setting. The authors
concluded that ‘‘… the distribution of CMR factors in a pri-
mary care database is similar to that established by pro-
spective national health surveys such as NAMCS. A key
method for identifying risk factors is using clinical outcomes,
including BMI and lab values. Future studies on metabolic
syndrome need to link clinically based information with
more readily available treatment and diagnosis information.’’
The second noteworthy study employing Centricity data is
Gill and Chen’s 2008 evaluation of lipid management (ie,
aCentricity Physician Office is a registered trademark of GE Medical Systems Information Technologies.
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adequacy of lipid testing, achievement of lipid goals, ap-
propriate use of lipid-lowering medication).20 The authors
note that ‘‘National EHR networks are excellent vehicles for
large outpatient quality of care studies, particularly for
measuring clinical outcomes such as lipid levels.’’ These
studies demonstrate that national EMR databases such as
Centricity are valuable tools for epidemiological, outcomes,
and health services research.
Methods
GE Centricity Database
The GE Centricity database captures patient-level clinical
data elements obtained from the Centricity Physician Office
EMR (formerly Logician) for Clinical Data Services (CDS) re-
porting. The Centricity EMR and its predecessors have been in
use for over 20 years, are certified by the Certification Com-
mission for Healthcare Information Technology, and are cur-
rently used by over 30,000 clinicians throughout the United
States. The CDS database contains data from 133 provider
groups with 7259 clinicians (including approximately 60%
primary care providers and 40% specialists) at 98 installations.
The CDS database includes de-identified, standardized data
on more than 8.9 million patients, with the median duration of
documentation being 985 days, or approximately 2.7 years.
Among the strengths of the Centricity database are its incor-
poration of documentation of a wide range of diagnostic and
therapeutic services, specifically laboratory test results (with
exact amounts and units of measurement) and medications
ordered, and, perhaps most important, inclusion of the above-
mentioned data at multiple points in time, allowing longitu-
dinal analyses not possible with most other data sets.
While the CDS database includes a large and diverse
group of providers, participation is voluntary, raising con-
cerns regarding self-selection by providers. For example, Gill
and Chen suggest that ‘‘practices that are more interested in
measuring (and improving) quality of care are more likely to
join MQIC [Medical Quality Improvement Consortium].’’20
Moreover, a recent study by Oderda et al21 that compared
the patient population in MQIC to the general US population
found that the MQIC population is older (with approxima-
tely 50% age 45 years or older, compared to 37% of the US
population), more likely to be from the northeast or midwest
regions (62% vs. 41%), and more likely to have commercial
insurance (73% vs. 59%) or Medicare (20% vs. 11%). How-
ever, the MQIC population is very similar in its racial dis-
tribution (79% vs. 81% white, 15% vs. 13% African
American). Although the proportion of patients with hy-
pertension in the MQIC database is virtually identical to that
of the US population (25.9% vs. 25.8%), according to data
from the National Health Interview Survey, the proportion
with diabetes is somewhat higher (9.8% vs. 7.4%). To sum-
marize, as Gill and Chen note, ‘‘while the MQIC population
differs somewhat from the general US population, it is un-
clear whether this reflects differences in persons who seek
care in outpatient settings, differences in providers who use
an EHR [electronic health record], or differences in providers
who use an EHR and join MQIC.’’20
Among the specific potential limitations of the Centricity
database are (1) invalid retrospective patient data, (2) un-
confirmed diagnoses, and (3) duplicate patient data. The
present research design addresses these 3 potential limita-
tions by applying inclusion/exclusion criteria to maximize
the validity of the data.
Inclusion/exclusion criteria
Exclusion of invalid retrospective patient data. When a
new provider’s data are entered into the Clinical Data Ser-
vices database, the visit dates may be back-filled, and thus
may be inaccurate (ie, the database entry date is assigned as
the visit date for activities that occurred long before that
date). As a result of the potential inaccuracy of visit dates, the
duration and prevalence of chronic conditions may be un-
derestimated. Therefore, the research design used herein
excludes patient data for the first year after the patient data
were initially entered into the database.
Exclusion of unconfirmed diagnoses. Patients merely
evaluated for a condition and patients with confirmed di-
agnoses have identical International Classification of Diseases,
Ninth Revision (ICD-9) codes in the database. Exclusion cri-
teria were developed to exclude instances when patients
were merely evaluated for a diagnosis (with no confirmation
of the evaluated diagnosis) through the following algorithm:
(a) include only records where the Diagnosis Qualifier con-
tains any of the phrases ‘‘diagnosis of,’’ ‘‘hospitalized for,’’
‘‘history of’’ (but not ‘‘family history of’’), ‘‘minor diagnosis
of,’’ ‘‘take note of,’’ ‘‘recurrence of,’’ or ‘‘status post’’; and (b)
exclude records where the Problem Concept description
contains any of the phrases ‘‘rule out,’’ ‘‘family history of,’’
‘‘risk of,’’ or ‘‘screening.’’
Further investigation may reveal that disease counts
should be supplemented with data derived from sources in
the database other than problems and explicit ICD-9 diag-
nosis codes. For instance, for diabetes, there may be a med-
ication record indicating regular use of insulin or oral
hypoglycemics for a patient with no ICD-9 diagnosis code
for diabetes in the database. Likewise, for hypertension,
there may be recorded observations of blood pressure for a
patient who may not have an ICD-9 diagnosis code for hy-
pertension in the database.
Exclusion of duplicate patient data. An exclusion algo-
rithm was applied to exclude cases for which there was
potential duplication of patient data as a result of a patient
visiting more than 1 Centricity client practice. This is critical
because the data are ‘‘anonymized’’ (ie, all unique patient
identifiers are removed in the de-identification process). To
avoid duplication of patients, the research design specified
exclusion of data originating from 3-digit zip codes con-
taining 3 or more providers who employ the Centricity EMR
system. The rationale for this exclusion criterion is that a
patient residing in a 3-digit zip code area that contains more
than 1 practice employing Centricity may appear in the da-
tabase as more than 1 patient.
In addition to applying the aforementioned inclusion/
exclusion algorithms, additional data (ie, diagnosis and
procedure codes, patient age) were obtained from the Cen-
tricity EMR database. Current Procedural Terminology
(CPT) code numbers indicating specific procedures can be
found in either the Order table or the Problem table, re-
quiring that both be mined to identify procedures. To iden-
tify each procedure, our design scanned all records in both of
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these tables to identify relevant CPT procedure codes. Like-
wise, age was derived from either the ‘‘Activity Fact’’ table or
the ‘‘Patient Dimension’’ table, with preference given to the
former table. A summary of the results of employing these
inclusion/exclusion algorithms is shown in Figure 1.
Analytic methods
Patient age groups used in the bivariate analyses are<18
years, 18–24, 25–34, 35–44, 45–54, 55–59, 60–64, 65–69,
and70. For simplicity, the age groups used in the multi-
variate analyses are<20, 20–39, 40–59, and60 years. The
narrower age ranges were selected so as to discern subtle
patterns as well as general ones. BMI categories are
BMI< 18.5, 18.5BMI< 25, 25BMI< 30, 30BMI< 35,
35BMI< 40, 40BMI< 45, 45BMI< 50, and BMI 50;
these categories were likewise selected to be sufficiently
narrow to detect subtle patterns. Racial/ethnic categories
include white, African American, Hispanic, Oriental/Asian,
Native American, Other, and Unknown.
In the initial analyses, contingency tables were used to
assess the bivariate relationships of BMI category, age group,
sex, and race/ethnicity with the diagnosed prevalence of
type II diabetes mellitus, hyperlipidemia, and hypertension.
Sets of 3-way tables stratified the relationships between BMI
category and diagnosed prevalence of the 3 diseases as a
function of age group, sex, and race/ethnicity. Next, a con-
tingency table was used to assess the relationship between
BMI category and the diagnosis of obesity per se. Finally,
logistic regressions were performed to summarize the effects
of demographic factors (age, sex, and race/ethnicity), obe-
sity, and comorbidities on the prevalence of each of the 3
conditions. These analyses consisted of an initial step in-
cluding only the demographic factors and obesity, and then a
second step adding the relevant comorbidities.
Results
Figures 2–5 and Table 1 present GE Centricity EMR results
for the number and percent distribution of patients with
diagnosed type II diabetes, hyperlipidemia, and hyperten-
sion, as a function of patient BMI, age group, race/ethnicity,
and sex, for the United States in 2005. The GE Centricity data
show that the prevalence of each condition is positively as-
sociated with both BMI and age (see Figs. 2 and 3). Figure 4
shows the associations between race/ethnicity and disease
prevalence, and indicates that African Americans have the
highest proportions of patients with diagnosed diabetes
(12.1%) and hypertension (28.9%), while whites have the
highest proportion with diagnosed hyperlipidemia (25.7%).
The associations between sex and disease prevalence are
shown in Figure 5, which portrays how males are more likely
than females to have each of the 3 conditions: 9.3% vs. 7.2%
have diabetes, 25.1% vs. 19.2% have hyperlipidemia, and
22.8% vs. 20.1% have hypertension.
As shown in Figures 2 and 3 and Table 2, the proportions
of patients with type II diabetes mellitus, hyperlipidemia,
and hypertension increase as both BMI and age increase.
Figures 6A, 6B, and 6C show the combined effects of BMI and
age on the prevalence of diabetes mellitus, hyperlipidemia,
GE Centricity database: 
N > 7,000,000 patients
Patients with recorded body mass index: 
N = 4,509,464
Patients appearing in the GE database: 
N = 4,021,069
Patients from 3-digit zip code areas with  
information from only 1 provider: 
N = 2,507,198
FIG. 1. Attrition flow diagram.
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FIG. 2. Diabetes, hyperlipidemia, and hypertension prevalence by BMI category.
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and hypertension, respectively. There are strong linear as-
sociations between both age and BMI and disease preva-
lence for all 3 conditions, and these associations are
consistently additive rather than interactive, that is, age and
BMI combine in a straightforward fashion without any
marked unpredictable interactions. Among the oldest pa-
tients (60) with the highest BMIs (50), the highest disease
prevalences are found: 50.0% for diabetes, 52.3% for hy-
perlipidemia, and 72.6% for hypertension. There are only a
few small inconsistencies in the linear relationships noted
between BMI and disease prevalence after stratifying by age
group; almost all of these inconsistencies reflect slightly
higher disease prevalence for the underweight (<18.5 BMI)
group compared to the next lowest BMI group (18.5
BMI< 25); these may reflect the effect of disease on under-
weight status rather than the effect of underweight status on
disease.
Table 3 shows the combined effects of BMI and sex on the
prevalence of diabetes, hyperlipidemia, and hypertension. As
noted above, males have a higher prevalence of all 3 condi-
tions, and the direct association between BMI and disease
prevalence is virtually identical for males and females.
Table 4 shows the combined effects of BMI and race/
ethnicity on the prevalence of diabetes, hyperlipidemia, and
hypertension. As was true for the combined effects of BMI
and sex, the positive association between BMI and disease
prevalence is highly consistent across all of the racial/ethnic
groups.
Table 5 presents results of the association between BMI
and the diagnosis of obesity. While BMI and reports of
obesity as a medical problem are positively associated, obesity
is substantially underreported. The medical definition of
obesity includes having a BMI of 30 or above. However, only
a little more than 10% of patients with 30BMI< 35 are
reported as obese, and only 57% were reported as obese at
the highly serious threshold of BMI 50.
The final analyses reported herein (Table 6) are logistic
regressions that summarize the effects of demographic fac-
tors, obesity, and comorbidities on the prevalence of each of
the 3 chronic conditions. These analyses begin with inclusion
of the demographic factors and obesity and then add the
relevant comorbidities. The analyses of diabetes prevalence
reinforce the findings presented above: Whites have a higher
risk of having diabetes than the reference category (odds
ratio [OR]¼ 1.377), but African Americans and Hispanics
have even higher odds (ORs¼ 2.201 and 2.754, respectively);
males have higher odds than females (OR¼ 1.517); increasing
age increases one’s odds of having diabetes (for each year,
OR¼ 1.060); and obesity leads to higher odds of having
diabetes (OR¼ 1.113).
FIG. 3. Diabetes, hyperlipidemia, and
hypertension prevalence by age group.
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FIG. 4. Diabetes, hyperlipidemia, and hypertension prevalence by race/ethnicity.
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Similarly, the logistic regression analyses of hypertension
prevalence reinforce the findings presented earlier: Whites
have a higher risk of having hypertension than the reference
category (OR¼ 1.257), and African Americans have even
higher odds (OR¼ 2.572), but the odds for Hispanics are
lower than those for whites (1.198); males have higher odds
than females (OR¼ 1.269); age increases one’s odds of hav-
ing hypertension (for each year, OR¼ 1.077); and obesity also
leads to higher odds (OR¼ 1.094).
The logistic regression analyses of hyperlipidemia preva-
lence also confirm the earlier findings: while whites have a
higher risk of having hyperlipidemia than the reference cat-
egory (OR¼ 1.275), African Americans and Hispanics have
lower odds (ORs¼ 0.911 and 0.937, respectively); males have
higher odds than females (OR¼ 1.560); age increases one’s
odds of having hyperlipidemia (for each year, OR¼ 1.062);
and obesity also leads to higher odds (OR¼ 1.059).
Discussion
The key role of obesity in the etiology of chronic disease in
the United States is a focus of health researchers, health
policy experts, and policy makers. For example, the Ameri-
can Heart Association and National Heart, Lung, and Blood
Institute Scientific Statement includes, as one of its 7 con-
clusions, that ‘‘in the United States, the [metabolic] syndrome
is strongly associated with the presence of abdominal obe-
sity.’’ The Statement also ‘‘recognizes several issues related to
the metabolic syndrome that require additional research for
Table 1. Proportion of Patients with Type II Diabetes Mellitus, Hyperlipidemia,
and Hypertension by Body Mass Index (BMI) Band, US, 2007
Type II Diabetes Hyperlipidemia Hypertension
Patient Characteristics n % n % n % Total % of Population
BMI Band
BMI<18.5 4,449 1.0% 11,187 2.4% 13,873 3.0% 466,836 12.9%
18.5BMI<25 32,286 2.9% 140,251 12.7% 128,133 11.6% 1,103,105 30.5%
25BMI<30 74,113 7.6% 271,118 27.9% 236,754 24.4% 971,308 26.9%
30BMI<35 77,841 13.3% 197,816 33.7% 193,810 33.0% 586,469 16.2%
35BMI<40 51,130 18.5% 93,623 33.9% 104,940 38.0% 276,517 7.7%
40BMI<45 27,382 22.2% 40,148 32.6% 50,201 40.8% 123,078 3.4%
45BMI<50 13,396 25.9% 16,274 31.4% 22,676 43.8% 51,774 1.4%
BMI50 10,137 29.1% 10,502 30.1% 16,456 47.2% 34,861 1.0%
Total 290,734 8.0% 780,919 21.6% 766,843 21.2% 3,613,948 100.0%
Age Band
Under 20 1,756 0.2% 4,269 0.5% 2,940 0.3% 883,151 24.4%
20–39 years 20,983 2.3% 66,254 7.1% 57,401 6.2% 931,816 25.8%
40–59 years 100,281 10.2% 298,927 30.3% 267,662 27.2% 985,418 27.3%
60 years 159,566 20.8% 389,476 50.8% 418,671 54.6% 766,812 21.2%
Missing 8,148 17.4% 21,993 47.0% 20,169 43.1% 46,751 1.3%
Total 290,734 8.0% 780,919 21.6% 766,843 21.2% 3,613,948 100.0%
Race
White 83,224 9.3% 229,191 25.7% 214,944 24.1% 891,188 24.7%
African American 21,316 12.1% 30,183 17.2% 50,872 28.9% 175,952 4.9%
Hispanic 3,660 7.5% 4,852 9.9% 5,287 10.8% 48,812 1.4%
Oriental/Asian 782 7.2% 1,594 14.7% 1,395 12.9% 10,841 0.3%
Native American 567 8.5% 930 13.9% 938 14.0% 6,692 0.2%
Other Race 1,997 6.4% 4,792 15.4% 5,043 16.2% 31,142 0.9%
Unknown 179,188 7.3% 509,377 20.8% 488,364 19.9% 2,449,321 67.8%
Total 290,734 8.0% 780,919 21.6% 766,843 21.2% 3,613,948 100.0%
Sex
Female 153,577 7.2% 410,588 19.2% 430,017 20.1% 2,135,205 59.1%
Male 137,132 9.3% 370,239 25.1% 336,762 22.8% 1,477,546 40.9%
Unknown 25 2.1% 92 7.7% 64 5.3% 1,197 0.0%
Total 290,734 8.0% 780,919 21.6% 766,843 21.2% 3,613,948 100.0%
0%
5%
10%
15%
20%
25%
30%
Type II Diabetes Hyperlipidemia Hypertension
Female
Male
FIG. 5. Diabetes, hyperlipidemia, and hypertension prev-
alence by sex.
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clarification. Foremost is the need for improved strategies
to achieve and sustain long-term weight reduction and
increased physical activity.’’22 Similarly, the Seventh Re-
port of the Joint National Committee on Prevention, De-
tection, Evaluation, and Treatment of High Blood Pressure
includes obesity along with hypertension, dyslipidemia,
and diabetes mellitus in its list of 9 major cardiovascular
risk factors.23
Utilizing the longitudinal data available in the GE Cen-
tricity EMR database, this study has assessed the associations
between obesity and 3 key chronic disease states: type II
diabetes, hyperlipidemia, and hypertension. The positive
association between obesity and the 3 comorbid conditions
in the GE Centricity database is similar to that found for the
US population using other data sets and methods. Although
obesity is underdiagnosed as an explicit problem in the
Centricity EMR, as it is in medical records generally, the
inclusion of BMI data in the Centricity database allows
identification of obesity and allows estimation of the degree
to which it is underreported.
The EMR data show both the high rates of prevalence of
the 3 chronic diseases and the significant role of obesity in
their etiology. Both bivariate and multivariate analyses
document the role of obesity in predicting and explaining the
prevalence of the 3 conditions and the value of the BMI data
found in the Centricity EMR. While the demonstrated impact
of obesity is strong, this impact is most likely underestimated
by using only 5 years of data, as was done in these analyses.
Further analyses should be performed utilizing a longer time
frame, an opportunity which will be facilitated by the ex-
panding use of EMRs in the future.
Additional implications of the current analyses relate to
optimal methods of analyzing EMR data. Specifically, ex-
clusion algorithms were used to exclude retrospectively en-
tered patient data, unconfirmed diagnoses, and duplicate
patient data. Further research is needed to assess the feasibility
and effectiveness of the existing techniques to maximize
validity, as well as the extension of these techniques and
development of additional ones.
Limitations
The limitations of this study originate primarily from 2
sources: (1) limitations of medical records in general and
EMRs in particular, and (2) limitations that have been iden-
tified in the GE Centricity EMR database in particular. All
medical records, manual or electronic, are subject to threats
to validity, although EMRs generally reduce data errors and
increase data validity compared to paper charts. For exam-
ple, EMRs eliminate the problem of illegibility; yet EMR
users can still make data entry errors. Similarly, regardless of
whether records are manual or electronic, there will be gaps
Table 2. Proportion of Patients with Type II Diabetes Mellitus, Hyperlipidemia,
and Hypertension, by Body Mass Index (BMI) Band and Age Group, US, 2007
Under 20 20–39 years 40–59 years 60 years
Yes % Yes % Yes % Yes % Total % of Population
Type II Diabetes
BMI<18.5 231 0.1% 325 1.4% 1,161 7.6% 2,653 12.9% 466,836 12.9%
18.5BMI<25 491 0.2% 2,038 0.6% 6,749 2.9% 22,489 11.2% 1,103,105 30.5%
25BMI<30 299 0.3% 3,462 1.3% 19,485 6.1% 49,025 17.7% 971,308 26.9%
30BMI<35 244 0.7% 4,499 2.9% 26,635 12.1% 44,152 27.0% 586,469 16.2%
35BMI<40 217 1.4% 4,212 5.3% 21,175 19.2% 23,792 36.1% 276,517 7.7%
40BMI<45 137 2.3% 2,946 7.6% 12,724 25.1% 10,642 42.7% 123,078 3.4%
45BMI<50 68 2.9% 1,804 10.5% 6,786 30.8% 4,328 47.8% 51,774 1.4%
BMI50 69 4.1% 1,697 14.3% 5,566 35.5% 2,485 50.0% 34,861 1.0%
Total 1,756 0.2% 20,983 2.3% 100,281 10.2% 159,566 20.8% 3,613,948 100.0%
Hyperlipidemia
BMI<18.5 472 0.1% 770 3.3% 2,911 18.9% 6,812 33.1% 466,836 12.9%
18.5BMI<25 1,171 0.4% 10,384 3.1% 40,763 17.5% 84,761 42.2% 1,103,105 30.5%
25BMI<30 933 1.1% 19,403 7.2% 97,513 30.6% 145,756 52.6% 971,308 26.9%
30BMI<35 777 2.2% 16,983 10.9% 81,514 37.1% 92,585 56.6% 586,469 16.2%
35BMI<40 494 3.3% 9,643 12.2% 42,604 38.6% 37,930 57.6% 276,517 7.7%
40BMI<45 251 4.1% 5,041 13.0% 19,494 38.4% 14,047 56.4% 123,078 3.4%
45BMI<50 102 4.3% 2,301 13.4% 8,357 37.9% 4,987 55.1% 51,774 1.4%
BMI50 69 4.1% 1,729 14.6% 5,771 36.8% 2,598 52.3% 34,861 1.0%
Total 4,269 0.5% 66,254 7.1% 298,927 30.3% 389,476 50.8% 3,613,948 100.0%
Hypertension
BMI<18.5 244 0.1% 768 3.3% 3,027 19.7% 9,604 46.7% 466,836 12.9%
18.5BMI<25 588 0.2% 5,971 1.8% 28,402 12.2% 90,876 45.3% 1,103,105 30.5%
25BMI<30 518 0.6% 12,604 4.6% 71,020 22.3% 146,657 52.9% 971,308 26.9%
30BMI<35 521 1.4% 13,955 9.0% 73,779 33.6% 99,886 61.1% 586,469 16.2%
35BMI<40 475 3.2% 10,569 13.3% 46,548 42.1% 44,067 66.9% 276,517 7.7%
40BMI<45 285 4.7% 6,555 16.9% 24,308 47.9% 17,455 70.0% 123,078 3.4%
45BMI<50 174 7.3% 3,650 21.2% 11,657 52.9% 6,517 72.0% 51,774 1.4%
BMI>50 135 8.0% 3,329 28.1% 8,921 56.8% 3,609 72.6% 34,861 1.0%
Total 2,940 0.3% 57,401 6.2% 267,662 27.2% 418,671 54.6% 3,613,948 100.0%
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FIG. 6. Prevalence of (A) diabetes, (B) hyperlipidemia, and (C) hypertension determined by body mass index (BMI)
category and age group.
158 CRAWFORD ET AL.
if information is not forwarded from one provider to an-
other, even though EMRs should eventually improve such
information exchange. Additionally, there may also be free
text data in an EMR that are not available for analysis be-
cause of the complexities and costs of text mining. Still, in
general, EMRs have great potential to mitigate many of the
above-mentioned problems.
The second class of methodological limitations, those
identified as potential problems in using GE Centricity EMR
data, include invalid retrospective patient data, unconfirmed
diagnoses, and duplicate patient data. As described earlier,
inclusion/exclusion algorithms were developed and applied
to address each of these issues. However, available data do
not allow comprehensive assessment of the success of this
strategy to eliminate all possible duplication and underesti-
mation/overestimation. A specific potential limitation of the
study stems from the fact that physicians’ diagnoses of hy-
pertension may not have taken into account that, for dia-
betics, hypertension is defined as systolic blood pressure
130 mmHg and diastolic blood pressure80 mmHg, while
for other populations, systolic blood pressure is defined
as140 mmHg and diastolic blood pressure is defined
as90 mmHg. However, it is unlikely that physicians failed
to take this distinction into account when making diagnoses
and recording problems. Still, to the degree that this dis-
tinction was ignored in physicians’ diagnoses, the present
analyses underestimate diabetes prevalence and probably
underestimate associations between prevalence of diabetes,
hypertension, and hyperlipidemia.
Conclusions
The study presented herein analyzes GE Centricity EMR
data in order to determine the effects of BMI and obesity, key
risk factors, and components of metabolic syndrome, on the
prevalence of 3 chronic diseases that have both high preva-
lence and high disease burdens: type II diabetes mellitus,
hyperlipidemia, and hypertension. While BMI and obesity
are often underreported in surveys and administrative
databases, EMR databases such as the GE Centricity EMR
database may be good sources of relevant data and may allow
tracking such variables over time, and facilitate longitudinal
analyses of increasing disease prevalence and progression.
This study demonstrates strong positive associations of
age, sex, race/ethnicity, BMI, and comorbidities with diag-
nosed prevalence of the 3 conditions. Results include uni-
form positive associations between both age and BMI and
the prevalence of each condition; uniformly greater preva-
lence for males than for females; and associations with
race/ethnicity, with African Americans having the highest
prevalence of diagnosed type II diabetes and hypertension
and whites having the highest prevalence of diagnosed
Table 3. Proportion of Patients with Type II Diabetes Mellitus, Hyperlipidemia,
and Hypertension, by Body Mass Index (BMI) Band and Sex, US, 2007
Female Male Total
n % n % n % of Population
Type II Diabetes
BMI<18.5 2,833 1.2% 1,615 0.7% 466,836 12.9%
18.5BMI<25 17,622 2.4% 14,660 3.9% 1,103,105 30.5%
25BMI<30 33,889 6.5% 40,221 8.9% 971,308 26.9%
30BMI<35 37,333 11.6% 40,500 15.3% 586,469 16.2%
35BMI<40 28,331 16.3% 22,794 22.2% 276,517 7.7%
40BMI<45 17,240 20.1% 10,139 27.1% 123,078 3.4%
45BMI<50 9,017 23.8% 4,379 31.7% 51,774 1.4%
BMI50 7,312 27.9% 2,824 32.8% 34,861 1.0%
Total 153,577 7.2% 137,132 9.3% 3,613,948 100.0%
Hyperlipidemia
BMI<18.5 7,714 3.2% 3,471 1.6% 466,836 12.9%
18.5BMI<25 89,920 12.4% 50,314 13.3% 1,103,105 30.5%
25BMI<30 125,288 24.0% 145,799 32.4% 971,308 26.9%
30BMI<35 92,833 28.9% 104,953 39.7% 586,469 16.2%
35BMI<40 51,387 29.6% 42,229 41.1% 276,517 7.7%
40BMI<45 25,019 29.2% 15,126 40.4% 123,078 3.4%
45BMI<50 10,888 28.7% 5,386 39.0% 51,774 1.4%
BMI50 7,539 28.7% 2,961 34.4% 34,861 1.0%
Total 410,588 19.2% 370,239 25.1% 3,613,948 100.0%
Hypertension
BMI<18.5 9,909 4.1% 3,961 1.8% 466,836 12.9%
18.5BMI<25 83,761 11.6% 44,363 11.7% 1,103,105 30.5%
25BMI<30 118,459 22.7% 118,274 26.3% 971,308 26.9%
30BMI<35 97,457 30.3% 96,335 36.4% 586,469 16.2%
35BMI<40 60,297 34.7% 44,637 43.5% 276,517 7.7%
40BMI<45 32,558 38.0% 17,639 47.2% 123,078 3.4%
45BMI<50 15,584 41.1% 7,092 51.3% 51,774 1.4%
BMI50 11,992 45.7% 4,461 51.8% 34,861 1.0%
Total 430,017 20.1% 336,762 22.8% 3,613,948 100.0%
EMR-BASED DISEASE PREVALENCE 159
hypertension. Despite the differences in disease prevalence
by sex and by racial/ethnic group, the positive associations
between BMI and disease prevalence are consistent for males
and females and across all racial/ethnic groups. Finally, the
logistic regression analyses control for possible confounding
and demonstrate the unique effects of each of the factors—
age, sex, racial/ethnic group, obesity, and comorbidities—
in explaining and predicting the prevalence of the 3 chronic
conditions. All of these results contribute to the grow-
ing literature regarding the adverse effects of obesity and
Table 4. Proportion of Patients with Type II Diabetes Mellitus, Hyperlipidemia, and Hypertension,
by Body Mass Index (BMI) Band and Race/Ethnicity, US, 2007
White African American Hispanic Oriental/Asian Native American
n % n % n % n % n % n % of Population
Diabetes Type II
BMI<18.5 1,343 1.3% 423 1.4% 43 0.3% 19 0.9% 9 0.7% 466,836 12.9%
18.5BMI<25 9,157 3.4% 2,113 5.2% 405 3.1% 277 5.6% 63 3.4% 1,103,105 30.5%
25BMI<30 21,065 8.7% 4,750 12.5% 1,039 10.2% 257 10.4% 139 8.2% 971,308 26.9%
30BMI<35 22,247 14.9% 5,387 17.8% 1,030 16.5% 151 17.5% 149 14.5% 586,469 16.2%
35BMI<40 14,922 21.0% 3,960 21.9% 584 20.3% 47 20.1% 103 22.7% 276,517 7.7%
40BMI<45 7,847 24.8% 2,332 24.0% 328 27.9% 17 20.0% 58 31.2% 123,078 3.4%
45BMI<50 3,788 28.6% 1,241 26.5% 121 25.8% 10 38.5% 24 30.0% 51,774 1.4%
BMI50 2,855 33.3% 1,110 28.6% 110 32.1% 4 30.8% 22 30.6% 34,861 1.0%
Total 83,224 9.3% 21,316 12.1% 3,660 7.5% 782 7.2% 567 8.5% 3,613,948 100.0%
Hyperlipidemia
BMI<18.5 3,564 3.4% 469 1.5% 61 0.4% 31 1.4% 15 1.1% 466,836 12.9%
18.5BMI<25 41,590 15.4% 3,617 8.9% 616 4.7% 618 12.5% 145 7.7% 1,103,105 30.5%
25BMI<30 78,187 32.2% 8,134 21.3% 1,689 16.5% 601 24.3% 309 18.3% 971,308 26.9%
30BMI<35 57,825 38.6% 8,037 26.6% 1,356 21.8% 240 27.9% 240 23.4% 586,469 16.2%
35BMI<40 27,835 39.2% 5,061 27.9% 658 22.9% 66 28.2% 134 29.6% 276,517 7.7%
40BMI<45 12,077 38.2% 2,655 27.3% 280 23.8% 26 30.6% 50 26.9% 123,078 3.4%
45BMI<50 4,875 36.8% 1,221 26.1% 116 24.7% 10 38.5% 20 25.0% 51,774 1.4%
BMI50 3,238 37.7% 989 25.5% 76 22.2% 2 15.4% 17 23.6% 34,861 1.0%
Total 229,191 25.7% 30,183 17.2% 4,852 9.9% 1,594 14.7% 930 13.9% 3,613,948 100.0%
Hypertension
BMI<18.5 4,096 3.9% 1,146 3.8% 72 0.5% 45 2.0% 23 1.8% 466,836 12.9%
18.5BMI<25 37,021 13.7% 6,683 16.4% 663 5.1% 490 9.9% 115 6.1% 1,103,105 30.5%
25BMI<30 66,549 27.4% 12,721 33.4% 1,661 16.2% 496 20.0% 271 16.1% 971,308 26.9%
30BMI<35 53,647 35.8% 12,645 41.9% 1,426 22.9% 247 28.7% 251 24.5% 586,469 16.2%
35BMI<40 29,172 41.1% 8,386 46.3% 816 28.4% 70 29.9% 160 35.3% 276,517 7.7%
40BMI<45 13,915 44.0% 4,728 48.6% 360 30.6% 28 32.9% 58 31.2% 123,078 3.4%
45BMI<50 6,171 46.5% 2,376 50.8% 157 33.5% 14 53.8% 30 37.5% 51,774 1.4%
BMI50 4,373 51.0% 2,187 56.3% 132 38.5% 5 38.5% 30 41.7% 34,861 1.0%
Total 214,944 24.1% 50,872 28.9% 5,287 10.8% 1,395 12.9% 938 14.0% 3,613,948 100.0%
Table 5. Proportion of Actual Diagnosis of Obesity
by Body Mass Index (BMI) Band*
BMI Band Total
Obesity
Diagnosis
Obesity
Diagnosis %
BMI<18.5 311,513 1,921 0.6%
18.5BMI<25 760,079 3,381 0.4%
25BMI<30 683,330 15,932 2.3%
30BMI<35 412,522 42,187 10.2%
35BMI<40 193,518 43,458 22.5%
40BMI<45 86,010 30,209 35.1%
45BMI<50 36,068 16,489 45.7%
BMI50 24,158 13,728 56.8%
Total 2,507,198 167,305 6.7%
*ICD-9-CM diagnosis codes 278.00 and 278.01
Table 6. Logistic Regression Analyses: Each
Diagnosis by Demographics and Obesity, without
and with Comorbid Conditions
Significance Odds ratio
Type II Diabetes Diagnosis
White 0.000 1.377
African American 0.000 2.201
Hispanic 0.000 2.754
Age 0.000 1.060
Obesity 0.000 1.113
Sex 0.000 1.517
Hypertension
White 0.000 1.257
African American 0.000 2.572
Hispanic 0.000 1.198
Age 0.000 1.077
Obesity 0.000 1.094
Sex 0.000 1.269
Hyperlipidemia
White 0.000 1.275
African American 0.000 0.911
Hispanic 0.001 0.937
Age 0.000 1.062
Obesity 0.000 1.059
Sex 0.000 1.560
Variable(s) entered: White, African American, Hispanic, age,
obesity, sex.
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demonstrate the value of EMR databases for studying and
documenting such effects.
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